Conflits d intérêt Astra-Zeneca, BMS, MSD, Novartis, Pfizer, Daiichi-Sankyo, Servier, CRAM, AFSSAPS, ARH Région de Bourgogne Clos Vougeot

Similar documents
Decision for fibrinolysis or primary PCI in the prehospital phase

Recommendations for criteria for STEMI systems of care: A focus on pharmacoinvasive strategies

SHOULD A REGIONAL STEMI CENTRE ONLY OFFER PRIMARY PCI?

Treatment of ST-elevation myocardial infarction in China: Where are we?

STEMI Linee guida ESC Maddalena Lettino, Italy

Daily practice of ACS management in the Gulf: Data from Gulf COAST

Thrombolysis in Cardiology to whom? Professor Steen D. Kristensen, MD, DMSc, FESC Department of Cardiology

Patient Transfer. Mark de Belder The James Cook University Hospital Middlesbrough

Hospital Ranking Based on Discharge Prescriptions After Acute Myocardial Infarction: A National Assessment over Three Consecutive Years

How to manage ACS patients with Comorbidities? Patients with Renal Failure

STREAM - ONE YEAR MORTALITY STRATEGIC REPERFUSION EARLY AFTER MYOCARDIAL INFARCTION. STREAM 1Y AHA 2013 P Sinnaeve

The Strategic Reperfusion Early After STEMI study Implications for clinical practice

Primary Percutaneous Coronary Intervention

Lessons learned From The National PCI Registry

No conflict of interest to declare

Dashboard and Outcomes Report with Case Studies

Effect of upstream clopidogrel treatment in patients with ST-segment elevation myocardial infarction undergoing primary PCI

S. CHASSAING4 P. DEQUENNE5

10-Year Mortality of Older Acute Myocardial Infarction Patients Treated in U.S. Community Practice

ACUTE CORONARY SYNDROME PCI IN THE ELDERLY

Clinical Seminar. Which Diabetic Patient is a Candidate for Percutaneous Coronary Intervention - European Perspective

Characteristics of Transient ST-Elevation versus ST-Elevation and Non-ST-Elevation Myocardial Infarction

CPORT E Trial. Atlantic C PORT

DISCUSSION QUESTION - 1

A.K. Gitt, F. Towae, C. Juenger, A. Papp, R. Zahn, U. Zeymer, J. Senges For the STAR-Study-Group Herzzentrum Ludwigshafen, Germany

Antiplatelet Agents in Acute Coronary Syndromes, NSTE-ACS

Platelet function testing to guide P2Y 12 -inhibitor treatment in ACS patients after PCI: insights from a national program in Hungary

I have no financial relationships to disclose

Current Advances and Best Practices in Acute STEMI Management A pharmacoinvasive approach

Controversies on Primary angioplasty in STEMI

Myocardial Infarction In Dr.Yahya Kiwan

GWTG-CAD: Mission: Lifeline Focus July 2017 PMT FORM SELECTION. Pre-Hospital/Arrival

Patient and System Time Delay

What oral antiplatelet therapy would you choose? a) ASA alone b) ASA + Clopidogrel c) ASA + Prasugrel d) ASA + Ticagrelor

Improving STEMI outcomes in Denmark. Michael Rahbek Schmidt, MD, PhD. Aarhus University Hospital Skejby Denmark

On admission Acute extensive anterior STEMI

Chest pain and troponins on the acute take. J N Townend Queen Elizabeth Hospital Birmingham

Prasugrel vs. Ticagrelor in ACS/PCI Which one to choose? V. Voudris MD FESC FACC 2 nd Cardiology Division Onassis Cardiac Surgery Center

Pharmaco-Invasive Approach for STEMI

P2Y 12 blockade. To load or not to load before the cath lab?

Prof. Adel El Etriby Ain Shams Faculty of Medicine

Update Guidelines in STEMI Management: Focus on Logistic and System Approach to Reperfusion Therapy

Patient characteristics Intervention Comparison Length of followup

2013 ACCF/AHA Guideline for the Management of ST-Elevation Myocardial Infarction

The Role of DHMC as an ST Elevation Myocardial Infarction Receiving Center in a Regional STEMI Care Network:

STEMI Stents What next? Arshad Khan - HNE Clinical Research Fellow. Supervisors: Prof Boyle and Attia.

A Future for the IABP in Cardiogenic Shock? Holger Thiele Medical Clinic II (Cardiology/Angiology/Intensive Care) University of Lübeck, Germany

1 a) Please confirm or deny whether your Trust has admitted patients for acute myocardial infarction in 2008/09, 2009/10 or 2010/11

STEMI update. Vijay Krishnamoorthy M.D. Interventional Cardiology

Data Elements and Definitions with Case Studies. Interpreting Your Outcomes Reports. Kim Hustler, Clinical Quality Consultant, NCDR

Ticagrelor compared with clopidogrel in patients with acute coronary syndromes the PLATO trial

The Window for Fibrinolysis. Frans Van de Werf, MD, PhD Leuven, Belgium

Downloaded from:

Overcoming the Risk-Treatment Paradox in Non-STE ACS: It s Time! Christopher Granger, MD

Acute Coronary Syndrome

Frans Van de Werf, MD, PhD Leuven, Belgium

Joo-Yong Hahn, MD/PhD

Acute Coronary Syndromes

KCS Congress: Impact through collaboration

Acute Coronary Syndrome (ACS) is the consequence of

Facilitated Percutaneous Coronary Intervention in Acute Myocardial Infarction. Is it beneficial to patients?

Version 4.4. Institutional Outcomes Report 2014Q3. National Outcomes Report Aggregation Date: Jan 12, :59:59 PM

Coronary Catheterization and Percutaneous Coronary Intervention in China 10-Year Results From the China PEACE-Retrospective CathPCI Study

Institutional Outcomes Report 2012Q2 Sample Hospital

New Insights on Reperfusion Choices Implications of STREAM. Paul W Armstrong MD

Optimal lenght of DAPT in different clinical scenarios

STEMI, Non-STEMI, Chest Pain?

Why and How Should We Switch Clopidogrel to Prasugrel?

Medical Management of Acute Coronary Syndrome: The roles of a noncardiologist. Norbert Lingling D. Uy, MD Professor of Medicine UERMMMCI

Adults With Diagnosed Diabetes

Relationships Relevant to this Presentation

The Need for Rescue PCI after Failed Fibrinolysis: Who, When and Why.

Use of Anticoagulant Agents and Risk of Bleeding Among Patients Admitted With Myocardial Infarction

The Evolving ACC-NCDR Programs: What you need to know for your practice

Level One STEMI Connecting the Dots changing Points of Care into Systems of Care

Prise en charge du SCA ST + en urgence. 9803mo01, 1

Quality Standards for Patients Treated by PCI. Peter F Ludman

APPENDIX F: CASE REPORT FORM

Opinion 15 May ARIXTRA 2.5 mg/0.5 ml, solution for injection in pre-filled syringe B/10 (CIP: )

An update on the management of UA / NSTEMI. Michael H. Crawford, MD

Antithrombotic treatment in ACS: what do the guidelines say? Nicolas Danchin, HEGP, Paris France

Statin pretreatment and presentation patterns in patients with acute coronary syndromes

Asian AMI Registry Session The 17 th Joint Meeting of Coronary Revascularization (JCR 2017) Busan, Korea Dec 8 th 2017

Update on Antithrombotic Therapy in Acute Coronary Syndrome

Speaker s name: Thomas Cuisset, MD, PhD

Mode of admission and its effect on quality indicators in Belgian STEMI patients

Updated and Guideline Based Treatment of Patients with STEMI

Is it worth offering cardiovascular disease prevention to the elderly? Prof. Dr. Helmut Gohlke Herz-Zentrum Bad Krozingen, Germany

Implementation of myocardial system of care in a rural area in Brazil using telecardiology

Antithrombotic Therapy in ACS Pretreatment in STEMI. Christian W. Hamm Kerckhoff Heart & Thorax Center Bad Nauheim Germany

Acute Coronary Syndromes. January 9, 2013 Chris Chiles M.D. FACC

Risk Stratification of ACS Patients. Frans Van de Werf, MD, PhD University of Leuven, Belgium

Oral anticoagulation/antiplatelet therapy in the secondary prevention of ACS patients the cost of reducing death!

Management of Acute Myocardial Infarction

La fibrinolyse est- elle sous- u1lisée en France?

Chest Pain. Dr Robert Huggett Consultant Cardiologist

Clinical Case. Management of ACS Based on ACC/AHA & ESC Guidelines. Clinical Case 4/22/12. UA/NSTEMI: Definition

I have nothing to disclose.

Case Challenges in ACS The Very Elderly in the Cath Lab

DES in primary PCI for STEMI: contra

Transcription:

Conflits d intérêt Astra-Zeneca, BMS, MSD, Novartis, Pfizer, Daiichi-Sankyo, Servier, CRAM, AFSSAPS, ARH Région de Bourgogne Clos Vougeot Agrément FMC N 100 437

Popul. millions Area km2 Density inha/km2 NORD 2,5 5 743 447 Essonne 1,2 1 804 668 Hte Garonne 1,2 6 309 193 Hte Savoie 0,7 4 388 163 Côte d Or 0,5 8 763 60 Nord Essonne Côte-d Or Haute-Savoie Haute-Garonne # 6

Demographic characteristics 200 patients analysed Côte- d Or : 29 Haute- Garonne : 39 Nord : 57 Haute- Savoie : 37 Essonne : 38 Almost 3/4 of males : 72,5 % male

Demographic characteris<cs Mean age : 63,3 yrs with regional differences : 69,4 yrs in Côte- d Or 60,0 yrs in Essonne More than half of pa<ents re<red (54 %), with regional differences 74,1 % in Côte- d Or 40,5 % in Essonne

Risk factors and medical history Hypertension : 43,5 % Diabetes : 21,4 % AcYve smoking : 44,9 % Mean weight : 77 kg BMI 30 : 20,8 % CAD known prior to admission : 19,7 %

First aid Chest pain reported in 93,9 % of cases In 3/4 of cases (71,1 %), chest pain triggers a phone call Emergency number 15 : only in 49 % of cases Emergency ambulance (SAMU/SMUR) is the 1st medical contact in less than 50 % of cases

Revascularisa<on modes Popula<on Age Female (%) Occupa<on (%) Employed Unemployed ReYred Fibrinolysis Primary PCI no reperfusion p 22 % 64 % 14 % < 0,001 63 ± 13 23 % 62 ± 13 24 % 70 ± 12 50 % < 0,01 < 0,02 44 5,1 51,3 41 8,1 50,5 22 4,3 73,9 Pa<ents without reperfusion : older Half are female ¼ are employed 0,32

14 22 Primary PCI Thrombolysis No reperfusion64 France Widimsky P et al, Eur Heart J 2010; 31:943-57.

Pa<ents referred directly to an interven<onal cardiology unit sympto m onset 1er call 33 min FMC 20 min Admission 54 min P PCI 43 min 97 min Preferred strategy is direct hospitalisation to cath-lab 64 % as an average 70,2 % if patient referred by medical ambulance

Pa<ents referred to peripheral centres Symptom onset Admission to the cath lab FMC 163 min 204 min Mean delay was more than double 227 min P PCI

% hospital mortality $% Effects of numbers of actors 9,7 # " 4,2 5,5! &'$ % () Nr of actors

Population USIK USIC FAST-MI FAST-MI 1995 2000 2005 2010 2152 2320 3059 3069 patients 373 centres patients 369 centres patients 223 centres patients 213 centres 1536 STEMI 1844 STEMI 1611 STEMI 1716 STEMI

FAST-MI 2010 213 centres Inclusion from October 2010 4169 patients included 3079 patients included during the first month

Proportion of STEMI patients from 1995 to 2010 Generalised use of troponin measurement

Admission diagnosis: STEMI vs NSTEMI

First place of arrival STEMI 38+11.5% call SAMU first NSTEMI 21% call their GP first 19% go to ER 29+8% call SAMU first 27% call their GP first 19% go to ER

Increased % of younger women

Time to first call in STEMI patients 2000 2005 2010 Median 138 90 74 25 th ; 75 th percentiles 60; 480 30; 287 30; 240 % of patients calling 60 min from onset

Use of the SAMU/firebrigade in STEMI Use of the SAMU/ FB in patients with STEMI 2005 2010

Reperfusion therapy in STEMI

STEMI: early mortality according to use and type of reperfusion therapy 2.1 2.6-48 % - 74 % - 70 %

30-day mortality: STEMI & NSTEMI 5?

Mortality according to timing of PCI after thrombolysis FAST-MI 2005 All patients with PCI after lysis Systematic pharmaco-invasive Rescue or symptom-driven PCI No PCI PCI 128 minutes PCI 129-220 minutes PCI > 220 minutes

Genetic determinants of clopidogrel response and clinical events in FAST-MI 2005 FAST- MI registry 2,208 patients with AMI, followed for one year Number of CYP2C19 loss- of- function alleles Simon et al. NEJM 2009

Early prescription of statins is associated with lower risk of developing acute AF % of patients developing AF Danchin et al. Heart 2010

LMWH vs UFH in elderly patients Survival in propensity score-matched cohorts Any blood Puymirat et al. Int J Cardiol 2012 transfusion Adjusted OR [95% CI] Major bleeding 0.41 [0.20-0.83] 0.49 [0.28-0.85]

Standard vs loading dose of clopidogrel in elderly patients: FAST-MI 2005 One-year event-free survival Adjusted HR (95%CI): 0.92 (0.68-1.25) Bleeding or Puymirat et al. transfusion Am J Cardiol 2011 Adjusted OR [95% CI] In-hospital death 0.91 [0.50-1.68] 1.03 [0.49-2.17]

Conclusion Periodical surveys are a unique tool to document the evolution of management and outcomes in patients admitted with AMI. Both the organisation of care and acute management have considerably evolved in the past 15 years.

Conclusion Early mortality has impressively decreased, both for STEMI and NSTEMI patients. The improved outcome in AMI patients is not related to one single therapeutic measure, but rather results from an improvement in the overall process of care. There are many lessons to be learned from such surveys.